Evidence map›Paper›PMID 41509223›Full record

ArticlebioRxiv : the preprint server for biology2025

Conserved Neuronal-like and Secretory Programs Define the Spatial Architecture of Gastroenteropancreatic Neuroendocrine Tumors.

Julie Karam, Samantha E Hoffman, Amanda Garza, Dan Gui, Hannah I Hoffman, Breanna M Titchen, Yutaro Tanaka, Erica Pimenta, Theodora Pappa, Laura Valderrabano and 8 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Julie KaramDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0009-0000-6908-4829
Samantha E HoffmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-6752-172X
Amanda GarzaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Dan GuiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Hannah I HoffmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Breanna M TitchenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Yutaro TanakaBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Erica PimentaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Theodora PappaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Laura ValderrabanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Kevin BiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Riaz GillaniBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Lauren BraisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Erin ShannonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jason L HornickDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jihye ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jennifer ChanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-0201-4444

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
The Cellular Geography of Therapeutic Resistance in CancerU2CCA233195 · NCI · DANA-FARBER CANCER INST · PI JOHNSON, BRUCE E. · 2018 to 2023
$13.7M
Molecular Origins and Evolution to Chemoresistance in Germ Cell TumorsR37CA222574 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2024
$3.2M
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
NCI NIH HHS R01 CA227388NCI NIH HHS R37 CA222574NCI NIH HHS U2C CA233195NIGMS NIH HHS T32 GM144273
6 · The paper itself

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are clinically heterogeneous malignancies whose biology and microenvironmental organization remain poorly understood. Here, we integrated single-nucleus multiomic (snRNA-seq and snATAC-seq) and spatial transcriptomic profiling across 38 well-differentiated pancreatic (pNET) and small-intestinal (siNET) tumors to define conserved malignant programs, their regulatory circuits, and spatial niches. We observed two conserved malignant cell programs spanning a continuous transcriptional spectrum: a neuronal-like program (si-cNMF1/p-cNMF1), and a secretory neuroendocrine program (si-cNMF2/p-cNMF2). Matched chromatin accessibility profiles uncovered distinct, tissue-specific regulatory networks, including

Identifiers

PMID41509223
PMCPMC12776270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.